As many biological products face losing their patents in the next decade, the pharmaceutical industry needs an abbreviated regulatory pathway for approval of biosimilar drug products, which are cost-effective, follow-on/subsequent versions of the innovator”s biologic products. But scientific challenges remain due to the complexity of both the manuf
购买此电子书可免费获赠一本!
格式 PDF ● 网页 444 ● ISBN 9781466579705 ● 出版者 CRC Press ● 发布时间 2013 ● 下载 6 时 ● 货币 EUR ● ID 2715426 ● 复制保护 Adobe DRM
需要具备DRM功能的电子书阅读器